Search

News Frequency of Participation in Sports Activities and the Risk of Injury in Children with Hemophilia

In children with hemophilia, numerous positive effects of physical activity on their health have been described. However, due to concerns about injuries and joint bleeding, young hemophiliacs may often be limited in real participation in sports life. Results from published studies, however, indicate that with proper therapy, the frequency of injuries is similar to that of the general population.

Source: Hemophilia with Movement 22. 9. 2022

News Efficacy of Reduced Dose Tumor Necrosis Factor Inhibitors in Axial Spondyloarthritis

The introduction of tumor necrosis factor inhibitors marked a breakthrough in the treatment of axial spondyloarthritis and other autoimmune diseases. One disadvantage of using these drugs can be increased susceptibility of patients to various infectious agents. The aim of the presented meta-analysis was therefore to determine whether a reduced dose of TNF inhibitors provides the same efficacy with a more favorable safety profile compared to the standard dosing regimen.

Source: Arthritis 9. 7. 2020

News Safety of Dabigatran in the Secondary Prevention of Venous Thromboembolism in Children

The direct thrombin inhibitor dabigatran is used by adult patients, among others, in the secondary prevention of venous thromboembolism (VTE). Its safety in the pediatric population was the focus of the international phase III study presented below.

Source: Anticoagulant Treatment 29. 9. 2020

News Observational Study of Pegylated rVIII Administration in Real Clinical Practice

A recently published article by American hematologists provided valuable information about the treatment with pegylated recombinant factor VIII (rVIII) in real clinical practice. This is the most extensive observational study to date that evaluates the clinical effect of the treatment and at the same time compares the consumption of FVIII in people with hemophilia A who have changed medication from normal half-life (SHL) or extended half-life (EHL) concentrates to pegylated rVIII.

Source: Hemophilia 21. 9. 2020

News Cost Effectiveness of Netupitant/Palonosetron Combination in the Prophylaxis of Chemotherapy-Induced Nausea and Vomiting

A recently published study compared the costs of achieving a complete response to antiemetic therapy in the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) when using a combination of netupitant and palonosetron (NEPA) versus palonosetron alone, both administered with dexamethasone. The results showed significantly better cost-effectiveness for NEPA.

Source: Antiemetic Therapy 20. 1. 2020

News Physical Activity in Hemophiliacs and How to Ensure it Safely

Physical activity is beneficial −⁠ and this holds true for patients with hemophilia as well. New therapeutic modalities offer additional possibilities to optimize prevention so that, among other things, it allows hemophiliacs to engage in sports.

Source: Hemophilia with Movement 2. 9. 2020

News Which Anticoagulant Treatment Do Patients Prefer?

For patients with atrial fibrillation (AF) for whom anticoagulant therapy is indicated for stroke prevention, good adherence to treatment is crucial. A recent study evaluated their perception of dabigatran treatment in comparison with vitamin K antagonists.

Source: Anticoagulant Treatment 28. 8. 2020

News Thyroid Disease as a Side Effect of Nivolumab

Source: Case Studies from Immunooncology 4. 2. 2020

News Impact of Oral Antidiabetics on Heart Failure

Diabetes mellitus is primarily perceived as a risk factor for ischemic heart disease and general atherosclerotic complications. However, an equally significant problem is the association between diabetes and heart failure. This hypothesis is confirmed by the VALUE study, which primarily focused on arterial hypertension. Its results show that individuals with diabetes had a higher risk of heart failure compared to the risk of acute myocardial infarction.

Source: Diabetes 19. 1. 2020

News Dysregulation of microRNA Expression After Treatment with Anti-EGFR Antibodies

A team of researchers from Plzeň decided to verify whether treatment with anti-EGFR antibodies changes the expression of selected microRNAs in patients with metastatic colorectal carcinoma (mCRC). They have just published their findings in the autumn issue of the journal Cancer Genomics Proteomics.

Source: Colorectal Cancer 22. 10. 2020

News Panitumumab in 1st Line in Older Patients –⁠ Results of the PANDA Study

The phase II PANDA study evaluated the regimens FOLFOX + panitumumab versus 5-FU + panitumumab in the 1st line treatment of patients with wt-RAS/BRAF metastatic colorectal cancer (mCRC).

Source: Colorectal Cancer 22. 10. 2020

News Experiences with AHA in Two Czech Centers and Risk Factor Evaluation

This summer, the journal Haemophilia published the results of an analysis of data from a relatively large Czech cohort of patients with acquired hemophilia A (AHA). The goal was to identify risk factors associated with early death and AHA relapse. Additionally, the authors addressed the question of the effect of higher doses of corticosteroids on treatment outcomes and patient mortality.

Source: Hemophilia 18. 11. 2020

News Does Ixekizumab Have Long-term Effects on Improving Psoriatic Arthritis Symptoms?

The extension of the SPIRIT-P2 study brought results of ixekizumab in patients with psoriatic arthritis (PsA) after 3 years of use. The data below were presented as a poster presentation at the annual congress of the European League Against Rheumatism (EULAR), which was held virtually in June 2020.

Source: Biological Treatment 30. 11. 2020

News COVID-19: Specifics of Care for Individuals with Congenital Bleeding Disorders

The COVID-19 pandemic has significantly impacted nearly all medical fields. Alongside direct care focused on seriously ill patients, the pandemic also affects the care of chronic patients, including those with hemophilia. However, there is currently not much specific data available regarding experiences with COVID-19 in patients with hemophilia. The specifics of congenital bleeding disorders, especially in relation to the severe course of COVID-19, are discussed by Italian authors in their article published in the journal Seminars in Thrombosis and Hemostasis.

Source: Hemophilia 8. 2. 2021

News Brigatinib vs. Crizotinib in the Treatment of ALK-Positive NSCLC –⁠ Results of the Second Interim Analysis of the ALTA-1L Study

The anaplastic lymphoma kinase inhibitor brigatinib demonstrated superiority over crizotinib in the first interim analysis of the ALTA-1L study in terms of progression-free survival and improvement in health-related quality of life in patients with non-small cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK) gene rearrangement. The second interim analysis results published in 2020 confirm these primary findings.

Source: Non-Small Cell Lung Cancer 15. 2. 2021